CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 8,511 shares of common stock were withheld by the company at an implied value of $29.25 per share to cover tax obligations. After this withholding, he directly holds 653,448 shares of CareDx common stock.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported a routine tax-related share disposition. On this Form 4, 997 shares of common stock were withheld by the company to cover tax obligations tied to the vesting of restricted stock units, at a value of $29.25 per share. After this withholding, Novack directly holds 111,635 shares of CareDx common stock.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a Form 4 showing a tax-related share disposition rather than an open-market trade. On this date, 2,411 shares of common stock were withheld by the company at $29.25 per share to cover tax obligations tied to vesting restricted stock units. After this withholding, she directly owned 168,287 shares, which include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026.
CareDx, Inc. executive Keith Kennedy, the CFO and COO, reported a routine tax-related share disposition linked to equity compensation. The company withheld 2,930 shares of common stock at $29.25 per share to cover tax obligations arising from the vesting of restricted stock units, rather than an open-market sale. After this withholding, Kennedy directly holds 219,924 shares of CareDx common stock. His holdings also include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026, reflecting ongoing participation in employee ownership programs.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a combination of option exercises and share sales in June. He exercised employee stock options to acquire 70,000 shares of common stock at an exercise price of $8.20 per share across several transactions.
On June 26 and June 29, 2026, he sold a total of 40,000 shares of common stock in open-market transactions at a weighted average price of $29.244 per share, with individual prices ranging from $29.00 to $29.58. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance.
Following these transactions, Hanna directly holds 661,959 shares of CareDx common stock. The underlying options relate to an award vesting over four years, with one-quarter vesting on April 15, 2025 and the remainder vesting monthly thereafter, and expiring on April 14, 2034.
Common stockholder filed a Form 144 to sell 39,500 shares of common stock, dated 06/29/2026. The filing states the sale arises from an exercise of stock options and lists cash as the method.
The notice also lists recent 10b5-1 sales by John Hanna during the prior three months: 21,998, 17,683, 10,282, 4,835 and 100 shares with the corresponding proceeds shown.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 17,683 shares of Common Stock on June 15, 2026 at a weighted average price of $24.0274 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024.
After this transaction, he continues to directly hold 631,959 shares of CareDx common stock, according to the filing.
CareDx, Inc. director Hannah Valantine reported both an equity grant and a share sale. On June 12, 2026, she acquired 9,795 shares of Common Stock as a grant with no cash paid, represented by restricted stock units that vest 100% on the earlier of the one-year anniversary of grant or immediately before the first Annual Meeting after the grant date, subject to continuous service. On June 15, 2026, she sold 12,103 shares of Common Stock in an open-market transaction at a weighted average price of $23.1123 per share, with individual sale prices ranging from $23.00 to $23.30. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and she held 36,686 shares directly after the sale.
COURNOYER CHRISTINE reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Christine Cournoyer received a grant of 9,795 shares of common stock in the form of restricted stock units. The RSUs vest 100% on the earlier of one year after the grant date or immediately before the first annual meeting after the grant, subject to continued service. Following this grant, she directly holds 58,943 shares.
CareDx, Inc. reported that director Richard Bryan Riggsbee acquired 9,795 shares of common stock through a grant of restricted stock units. These RSUs were awarded at no cash cost per share and are a form of equity compensation, not an open-market purchase.
According to the filing, all of the RSUs vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the first Annual Meeting that occurs after the grant date, subject to his continuous service. Following this award, Riggsbee directly holds 39,312 shares of CareDx common stock.